SCHEMBL4468522

SCHEMBL4468522

Oc1ccc2c(c1)CC1(CCC1)CO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENTPD5 O75356 2/20 0.40
CETP P11597 1/20 0.40
CYP3A4 P08684 2/20 0.39
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RAB9A P51151 1/20 0.36
PTPN1 P18031 3/20 0.34
HIF1A Q16665 2/20 0.33
EPAS1 Q99814 2/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
AKT1 P31749 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30148835 0.80 BACE1 (0.41) MAPT
SCHEMBL30148868 0.77 BACE1 (0.38) MAPT
SCHEMBL28922769 0.77 BACE1 (0.38) MAPT
SCHEMBL30148841 0.75 AKR1B1 (0.40) CYP3A4MAPTALDH1A1KDM4EMEN1
SCHEMBL30148842 0.72 AKR1B1 (0.40) CYP3A4MAPTALDH1A1KDM4EMEN1
SCHEMBL28840800 0.70 BACE1 (0.41) MAPT
SCHEMBL28644317 0.67 OXTR (0.39) KMT2AMAOAMAOB
SCHEMBL31280223 0.67 ESR1 (0.41) ESR1ESR2MAOAMAOBPRKCI
SCHEMBL4473726 0.67 DRD2 (0.35) CYP3A4MAPTALDH1A1KDM4EMEN1
SCHEMBL28840755 0.67 BACE1 (0.38) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 ENTPD5 777/4885CETP 2291/4885CYP3A4 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.